Literature DB >> 7971710

Novel delivery of antioxidant enzyme catalase to alveolar macrophages by Fc receptor-mediated endocytosis.

J Harrison1, X Shi, L Wang, J K Ma, Y Rojanasakul.   

Abstract

Excessive production of reactive oxygen species by alveolar macrophages (AMs) in response to inhaled toxic substances is a major cause of oxidative lung injury. Therapeutic approaches designed to protect the lungs from oxidative injury by administering native antioxidant enzymes such as catalase and superoxide dismutase have been suggested. However, problems associated with poor penetration of these enzymes to the intracellular target sites have limited their effective use. The present study reports a drug targeting method based on receptor-mediated endocytosis of the antioxidant enzyme catalase to the AMs. This method employs molecular conjugate consisting of a cognate moiety, in this case IgG which recognizes the macrophage Fc receptor, covalently linked to the enzyme catalase via the reversible disulfide linkage. The uptake efficiency of the enzyme conjugate and its protection against oxidative injury were evaluated microfluorometrically using the intracellular oxidative probe dichlorodihydrofluorescein BSA: anti BSA antibody complex (DCHF-IC), and the cell viability indicator propidium iodide. The DCHF-IC-stimulated macrophages exhibited a dose- and time-dependent increase in intracellular fluorescence with a half maximal response dose of approximately 120 micrograms/ml. Free catalase (50-500 U/ml) failed to inhibit the DCHF-IC-induced oxidative burst and had only a marginal protective effect on AM injury. In contrast, the catalase-IgG conjugate (50-500 U/ml) strongly inhibited both the DCHF-IC-induced oxidation and injury in a dose-dependent manner. Effective inhibition was shown to require both the antioxidant catalase moiety ant the cognate moiety for the cell surface receptor. Specific internalization of the conjugate through the Fc receptor was also investigated by competitive inhibition using free IgG.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7971710     DOI: 10.1023/a:1018976529766

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Epigenetic interconversions of the multiple forms of mouse liver catalase.

Authors:  R S. Holmes; C J. Masters
Journal:  FEBS Lett       Date:  1970-11-09       Impact factor: 4.124

2.  Overview of the process of cellular injury in interstitial lung disease.

Authors:  P A Ward
Journal:  Chest       Date:  1991-07       Impact factor: 9.410

Review 3.  Antioxidant defenses in the lung.

Authors:  I Fridovich; B Freeman
Journal:  Annu Rev Physiol       Date:  1986       Impact factor: 19.318

4.  The failure of aerosolized superoxide dismutase to modify pulmonary oxygen toxicity.

Authors:  J D Crapo; D M DeLong; K Sjostrom; G R Hasler; R T Drew
Journal:  Am Rev Respir Dis       Date:  1977-06

Review 5.  Pathobiology of pulmonary fibrosis.

Authors:  E Crouch
Journal:  Am J Physiol       Date:  1990-10

6.  Properties of antibodies cytophilic for macrophages.

Authors:  A Berken; B Benacerraf
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

7.  Liposome-mediated augmentation of catalase in alveolar type II cells protects against H2O2 injury.

Authors:  B J Buckley; A K Tanswell; B A Freeman
Journal:  J Appl Physiol (1985)       Date:  1987-07

8.  Measurement of superoxide release in the phagovacuoles of immune complex-stimulated human neutrophils.

Authors:  T C Ryan; G J Weil; P E Newburger; R Haugland; E R Simons
Journal:  J Immunol Methods       Date:  1990-07-03       Impact factor: 2.303

9.  Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase.

Authors:  R V Padmanabhan; R Gudapaty; I E Liener; B A Schwartz; J R Hoidal
Journal:  Am Rev Respir Dis       Date:  1985-07

10.  Acute immunologic pulmonary alveolitis.

Authors:  K J Johnson; P A Ward
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

View more
  1 in total

Review 1.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.